Itolizumab is under clinical development by Biocon and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Pneumonia.

Sumeet Bagadia, executive director of Choice Broking, advised purchasing two stocks on Monday, December 30, since the Nifty ...

The Indian equity markets closed lower on Monday, December 30, as volatility dominated the trading session. The Nifty 50 ...

AM(IST)on Monday in a weak market. Biocon Ltd.(up 2.97 per cent), Abbott India Ltd.(up 2.24 per cent), Alkem Laboratories Ltd ...

Indian benchmark indices Nifty 50 and Sensex ended the previous trade session in the green. Nifty 50 closed at 23,813.40, ...

Healthcare stocks were trading in green, with the BSE Healthcare index increasing 25.87 points or 0.06% at 44663.98 at 09:33 IST.

The Nifty Pharma index closed 1.01 per cent at 23241.15. Benchmark NSE Nifty50 index ended down 168.5 points at 23644.9, ...

IST, the barometer index, the S&P BSE Sensex, declined 36.28 points or 0.05% to 78,662.79. The Nifty 50 index shed 17.35 points or 0.07% to 23,796.05.

This milestone builds on prior approvals for Biocon Biologics' Yesafili and Samsung Bioepis' Opuviz earlier in 2024. The ...

INR:5342. how many times does 6 go into 143 Bayer/Merck's new heart failure drug vericiguat has been approved for marketing ...

INR:8113. mighty mammoth paint job ats In difficult times, "integration of medical care and nursing care" may become the transformation direction of ...

India's biopharma sector marked notable achievements, with approvals of key biosimilars and the launch of advanced CAR-T ...